Payment overview · 2025
General Payments
$18.26
1 reported records · 1 companies
Healthcare provider profile · identity verified
Michael Deshaies, DO
Allopathic & Osteopathic Physicians|Internal Medicine · GLASTONBURY, CT · NPI 1376648634
Verified facts
What the public records show
CMS Open Payments records show Michael Deshaies, DO received $18.26 in general payments during 2025 across 1 reported records.
PFIZER INC. accounted for 100.0% of that reported general-payment amount.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.26 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $18.26 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
35 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 548 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 351 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 351 | 90 |
| Lisinopril | Lisinopril | 298 | 76 |
| Oxycodone Hcl | Oxycodone Hcl | 250 | 17 |
| Losartan Potassium | Losartan Potassium | 244 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 236 | 72 |
| Metformin Hcl | Metformin Hcl | 229 | 68 |
| Alprazolam | Alprazolam | 221 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 197 | 52 |
| Omeprazole | Omeprazole | 194 | 56 |
| Lorazepam | Lorazepam | 185 | 41 |
| Simvastatin | Simvastatin | 183 | 49 |
| Valsartan | Valsartan | 179 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 179 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 55 |
| Sertraline Hcl | Sertraline Hcl | 146 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 144 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 37 |
| Allopurinol | Allopurinol | 130 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 40 |
| Prednisone | Prednisone | 127 | 70 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 125 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 31 |
| Synthroid | Levothyroxine Sodium | 106 | 27 |
| Furosemide | Furosemide | 99 | 27 |
| Bupropion Xl | Bupropion Hcl | 93 | 13 |
| Tramadol Hcl | Tramadol Hcl | 90 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 83 | 14 |
| Gabapentin | Gabapentin | 82 | 30 |
| Ozempic | Semaglutide | 82 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 23 |
| Trazodone Hcl | Trazodone Hcl | 77 | 20 |
| Atenolol | Atenolol | 76 | 18 |
| Jardiance | Empagliflozin | 75 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 74 | 65 |
| Famotidine | Famotidine | 71 | 21 |
| Eliquis | Apixaban | 69 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 68 | 23 |
| Hydromorphone Hcl | Hydromorphone Hcl | 67 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 18 |
| Clonazepam | Clonazepam | 62 | 14 |
| Spironolactone | Spironolactone | 57 | 17 |
| Montelukast Sodium | Montelukast Sodium | 55 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 54 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 21 |
| Glipizide | Glipizide | 51 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 17 |
| Farxiga | Dapagliflozin Propanediol | 48 | 13 |
| Celecoxib | Celecoxib | 47 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 14 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 46 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 38 |
| Azithromycin | Azithromycin | 41 | 38 |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Lovastatin | Lovastatin | 36 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Meloxicam | Meloxicam | 35 | 16 |
| Paxlovid | Nirmatrelvir/Ritonavir | 35 | 35 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 17 |
| Irbesartan | Irbesartan | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 13 |
| Carvedilol | Carvedilol | 29 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 18 |
| Betamethasone Valerate | Betamethasone Valerate | 25 | 20 |
| Glipizide Er | Glipizide | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 17 |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 12 |
| Cephalexin | Cephalexin | 21 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 20 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 13 |
| Methylprednisolone | Methylprednisolone | 17 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Zoloft | Sertraline Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Klonopin | Clonazepam | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Zolmitriptan | Zolmitriptan | 12 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $18.26 · 1 records | PFIZER INC. | — | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error